OBR Daily Commentary

forumImage

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients

(BMS) Apr 2, 2019 - Bristol-Myers Squibb Company today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four studies, 14% of all Opdivo-treated patients were alive at four years. Notably, in patients with PD-L1 ≥1% and <1%, four-year overall survival (OS) rates were 19% and 11%, respectively. In the pooled analysis of the two phase 3 trials, CheckMate -017 and -057, the four-year OS rate for Opdivo-treated patients was 14% compared to 5% for docetaxel-treated patients. Additionally, exploratory landmark analysis of OS found that of patients who had a complete or partial response at six months, 58% of those treated with Opdivo were alive four years later vs. 12% of patients treated with docetaxel.

Read Article arrow

H. Jack West, MD (Posted: April 03, 2019)

quotesNice to see further long-term survival data, really in keeping with what we've seen up to now. There are a significant minority of patients who continue to demonstrate prolonged survival far beyond what we'd seen before the era of immune checkpoint inhibitor therapy in advanced NSCLC. That said, the world has shifted to using immunotherapy agents primarily first line in advanced NSCLC. These data don't suggest any change in management or our thinking.quotes

Add Comment 1 Comment
forumImage

Data From Two KEYNOTE Trials Show Pembrolizumab Benefited Patients With Advanced Small Cell Lung Cancer

(AACR 2019) Apr 1, 2019 - The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29–April 3.

Read Article arrow

H. Jack West, MD (Posted: April 01, 2019)

quotesThese data are really obviated by the new standard of carbo/etoposide with atezolizumab as first line treatment for extensive stage SCLC. It is difficult to impossible to see how these data would be relevant with patients with extensive stage SCLC routinely receiving first line atezolizumab. There is no reason to think that subsequent pembrolizumab would have any activity in this setting.quotes

Add Comment 1 Comment
forumImage

PharmaMar Announces Positive Results In Its Lurbinectedin Monotherapy Trial For Small Cell Lung Cancer

(PharmaMar) Mar 25, 2019 - PharmaMar today announced that its Phase II trial of lurbinectedin as a single agent for the treatment of relapsed small cell lung cancer (SCLC) has achieved its primary endpoint, by both investigator review and IRC (Independent Review Committee). The primary endpoint of this trial was to measure the Overall Response Rate (ORR), with other secondary endpoints such as Duration of Response (DOR), Progression- Free Survival (PFS), Overall Survival (OS) and safety.

Read Article arrow

H. Jack West, MD (Posted: March 25, 2019)

quotesThis was expected based on prior, preliminary presentation of data from this study, though every bit of positive results in small cell lung cancer (SCLC), particularly relapsed SCLC, is very welcome. Lurbinectedin has demonstrated good evidence of activity as a single agent or combined with doxorubicin, though single agent appears to have the better therapeutic index. Still, we await the results of phase III data with lurbinectedin before we can really establish a place for this agent in the management of patients with relapsed SCLC.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...